恆瑞醫藥(600276.SH)漲超4%欲再創新高 三季度收入超預期獲多家機構看好
格隆匯10月25日丨昨晚公佈業績的恆瑞醫藥(600276.SH)今早跳空高開後繼續上漲,現報86.44元,漲4.51%,逼近10月17日創出的歷史最高價86.86元,暫成交18.37億元,最新總市值3823億元。公司三季度營收69.19億元,同比增47.27%;實現歸母淨利潤13.22億元,同比增31.96%。公司還公佈,控股子公司瑞石生物的SHR0302鹼軟膏獲批臨牀;此外,恆瑞醫藥向NMPA遞交的0.25g、0.375g兩個規格的甲磺酸阿帕替尼片分別與依託泊苷膠囊聯用的臨牀試驗申請亦獲得受理。國金證券發佈研報指出,恆瑞醫藥三季報收入超預期,新藥放量符合預期,仿製藥略有提速,維持買入評級。中金最新報告表示,恆瑞醫藥第三季度收入超預期,預計新藥將保持強勁增長勢頭,上調目標價7.3%至95元,維持跑贏行業評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.